National Institute of Health and Clinical Excellence (NICE) - latest published guidance
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health. The guidance is developed using the expertise of the NHS and the wider healthcare community including NHS staff, healthcare professionals, patients and carers, industry and the academic world. For more details on their guidance visit their website.
NICE has issued the following guidance to the NHS in England and Wales (June 2012):
- Acute upper GI bleeding
- Autism in adults
- Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)
- Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
- Migraine (chronic) - botulinum toxin type A
- Prevention and control of healthcare-associated infections
- Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy)
- Sickle cell acute painful episode
- Venous thromboembolic diseases
Website: National Institute for Health and Clinical Excellence